| abstract |
The invention relates to the use of a compound of formula (I), its N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form, where Z is halogen; C1-6alkyl; C1-6alkyl substituted with hydroxy, carboxyl, cyano, amino, mono- or di (C1-6alkyl) amino, aminocarbonyl, mono- or di (C1-6alkyl) aminocarbonyl, C1-6alkyloxycarbonyl or C1-6alkyloxy; polyhalogen-C1-6alkyl; Salkyloxy; cyano; amino; aminocarbonyl; mono- or di (C1-6alkyl) aminocarbonyl; C1-6alkyloxycarbonyl; C1-6alkylcarbonyloxy; HN-S (= O); mono- or di (C1-6alkyl) amino-S (═O); -C (= N-R) NRR; Q represents an optionally substituted carbon cycle or an optionally substituted heterocycle; L is substituted phenyl or optionally substituted monocyclic 5- or 6-membered partially saturated or aromatic heterocycle or bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl for the manufacture of a medicament for the prevention or treatment of diseases mediated by TNF-α and / or IL-12. |